These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 32391234)

  • 21. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two distinct cases with COVID-19 in kidney transplant recipients.
    Kim Y; Kwon O; Paek JH; Park WY; Jin K; Hyun M; Lee JY; Kim HA; Han S
    Am J Transplant; 2020 Aug; 20(8):2269-2275. PubMed ID: 32337859
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
    Hung IF; Lung KC; Tso EY; Liu R; Chung TW; Chu MY; Ng YY; Lo J; Chan J; Tam AR; Shum HP; Chan V; Wu AK; Sin KM; Leung WS; Law WL; Lung DC; Sin S; Yeung P; Yip CC; Zhang RR; Fung AY; Yan EY; Leung KH; Ip JD; Chu AW; Chan WM; Ng AC; Lee R; Fung K; Yeung A; Wu TC; Chan JW; Yan WW; Chan WM; Chan JF; Lie AK; Tsang OT; Cheng VC; Que TL; Lau CS; Chan KH; To KK; Yuen KY
    Lancet; 2020 May; 395(10238):1695-1704. PubMed ID: 32401715
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of Interferon Beta 1a, compared to Interferon Beta 1b and the usual therapeutic regimen to treat adults with moderate to severe COVID-19: structured summary of a study protocol for a randomized controlled trial.
    Irvani SSN; Golmohammadi M; Pourhoseingholi MA; Shokouhi S; Darazam IA
    Trials; 2020 Jun; 21(1):473. PubMed ID: 32493468
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences between Clinical Protocols for the Treatment of Coronavirus Disease 2019 (COVID-19) in Andalusia, Spain.
    Pérez-Belmonte LM; López-Carmona MD; Quevedo-Marín JL; Ricci M; Martín-Carmona J; Sanz-Cánovas J; López-Sampalo A; Martín-Escalante MD; Bernal-López MR; Gómez-Huelgas R
    Int J Environ Res Public Health; 2020 Sep; 17(18):. PubMed ID: 32961675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case Report: Severe SARS-CoV-2 Infection Treated with Remdesivir in a Patient with ESRD.
    Patel RH; Pella PM; Haider N; Blanco R
    Infect Disord Drug Targets; 2022; 22(3):e011221198456. PubMed ID: 34852751
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and effectiveness of azithromycin in patients with COVID-19: An open-label randomised trial.
    Sekhavati E; Jafari F; SeyedAlinaghi S; Jamalimoghadamsiahkali S; Sadr S; Tabarestani M; Pirhayati M; Zendehdel A; Manafi N; Hajiabdolbaghi M; Ahmadinejad Z; Kouchak HE; Jafari S; Khalili H; Salehi M; Seifi A; Golestan FS; Ghiasvand F
    Int J Antimicrob Agents; 2020 Oct; 56(4):106143. PubMed ID: 32853672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. COVID-19 treatment with lopinavir-ritonavir resulting in sick sinus syndrome: a case report.
    Wang LY; Ng GYP
    Eur Heart J Case Rep; 2020 Oct; 4(FI1):1-6. PubMed ID: 33089048
    [TBL] [Abstract][Full Text] [Related]  

  • 29. COVID-19 in Children: Clinical Approach and Management.
    Sankar J; Dhochak N; Kabra SK; Lodha R
    Indian J Pediatr; 2020 Jun; 87(6):433-442. PubMed ID: 32338347
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: A structured summary of a study protocol for a randomised controlled trial.
    Denholm JT; Davis J; Paterson D; Roberts J; Morpeth S; Snelling T; Zentner D; Rees M; O'Sullivan M; Price D; Bowen A; Tong SYC;
    Trials; 2020 Jul; 21(1):646. PubMed ID: 32665040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical value of two combination regimens in the Management of Patients Suffering from Covid-19 pneumonia: a single centered, retrospective, observational study.
    Vahedi E; Ghanei M; Ghazvini A; Azadi H; Izadi M; Panahi Y; Fathi S; Salesi M; Saadat SH; Ghazale AH; Rezapour M; Mozafari A; Zand N; Parsaei MR; Ranjkesh MH; Jafari R; Movaseghi F; Darabi E
    Daru; 2020 Dec; 28(2):507-516. PubMed ID: 32562159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
    Sanders JM; Monogue ML; Jodlowski TZ; Cutrell JB
    JAMA; 2020 May; 323(18):1824-1836. PubMed ID: 32282022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A sporadic COVID-19 pneumonia treated with extracorporeal membrane oxygenation in Tokyo, Japan: A case report.
    Nakamura K; Hikone M; Shimizu H; Kuwahara Y; Tanabe M; Kobayashi M; Ishida T; Sugiyama K; Washino T; Sakamoto N; Hamabe Y
    J Infect Chemother; 2020 Jul; 26(7):756-761. PubMed ID: 32317225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment options for COVID-19: The reality and challenges.
    Jean SS; Lee PI; Hsueh PR
    J Microbiol Immunol Infect; 2020 Jun; 53(3):436-443. PubMed ID: 32307245
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019.
    Kim JW; Kim EJ; Kwon HH; Jung CY; Kim KC; Choe JY; Hong HL
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S253-S263. PubMed ID: 32536150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR.
    Lim J; Jeon S; Shin HY; Kim MJ; Seong YM; Lee WJ; Choe KW; Kang YM; Lee B; Park SJ
    J Korean Med Sci; 2020 Feb; 35(6):e79. PubMed ID: 32056407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Lingscheid T; Kinzig M; Krüger A; Müller N; Bölke G; Tober-Lau P; Münn F; Kriedemann H; Witzenrath M; Sander LE; Sörgel F; Kurth F
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0122922. PubMed ID: 36286542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Azithromycin added to hydroxychloroquine for patients admitted to intensive care due to coronavirus disease 2019 (COVID-19)-protocol of randomised controlled trial AZIQUINE-ICU.
    Duška F; Waldauf P; Halačová M; Zvoníček V; Bala J; Balík M; Beneš J; Klementová O; Kozáková I; Kubricht V; Le Roy A; Vymazal T; Řehořová V; Černý V;
    Trials; 2020 Jul; 21(1):631. PubMed ID: 32641163
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COVID-19 in Hemodialysis Patients: A Report of 5 Cases.
    Wang R; Liao C; He H; Hu C; Wei Z; Hong Z; Zhang C; Liao M; Shui H
    Am J Kidney Dis; 2020 Jul; 76(1):141-143. PubMed ID: 32240718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.